Plus Therapeutics, Inc. (PSTV) Tops Q3 EPS by 3c

Plus Therapeutics, Inc. (NASDAQ: PSTV) reported Q3 EPS of ($0.19), $0.03 better than the analyst estimate of ($0.22). Revenue for the quarter came in at $0 versus the consensus estimate of $0 .

For earnings history and earnings-related data on Plus Therapeutics, Inc. (PSTV) click here.

You May Also Be Interested In

• TPU-As-A-Service could boost Google’s 2028 profit by over 15%: Barclays
• Charter Communications (CHTR) Tops Q2 EPS by 66c
• HSBC starts SpaceX at Hold, sees execution risks tempering long-term AI ambitions